Determine the necessary mass, volume, or concentration for preparing a solution.
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC 50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3 , RIPK2 , DYRK3 , smMLCK and CLK2 . HTH-01-091 TFA can be uesd for breast cancer research.
Appearance:Solid
IC50& Target:IC50: 10.5 nM (MELK), 41.8 nM (DYRK3), 42.5 nM (RIPK2), 60.6 nM (PIM1), 108.6 nM (smMLCK), 632 nM (mTOR), 962 nM (PIK3CA), 1230 nM (CDK7), 1740 nM (GSK3A)
In Vitro:HTH-01-091 (1 μM) TFA selectively inhibits 4% of the kinases over 90%. HTH-01-091 (0-10 μM, 1 h) TFA is cell permeable and causes MELK degradation. HTH-01-091 (0-10 μM, 3 day) TFA exhibits minor antiproliferative effects in breast cancer cells.
Biological Activity:HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC 50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3 , RIPK2 , DYRK3 , smMLCK and CLK2 . HTH-01-091 TFA can be uesd for breast cancer research.